Wilson Sonsini Goodrich & Rosati represented Cleveland Diagnostics on the transaction. Cleveland Diagnostics, a clinical-stage biotechnology company developing next-generation diagnostic tests for the early detection of...
Cleveland Diagnostics’ $75 Million Financing
Oberland Capital’s $320 Million Investment in ImmunityBio
Wilson Sonsini Goodrich & Rosati represented ImmunityBio in the transaction. ImmunityBio, Inc., a clinical-stage immunotherapy company announced an up to $320 million royalty financing and equity...
Novartis’ Acquisition of DTx Pharma
Wilson Sonsini Goodrich & Rosati is advising DTx Pharma on the transaction. A preclinical-stage biotechnology company, DTx Pharma announced that it has been acquired by Novartis. In addition...
Hughes & Company’s Investment in Voluware
Wilson Sonsini Goodrich & Rosati represented Voluware on the deal. Voluware, an award-winning provider of solutions to speed and simplify prior authorizations, announced a capital investment...
LinusBio’s $16 Million Financing to Help Diagnose Autism
Wilson Sonsini advised LinusBio on the deal. Linus Biotechnology received $16 million in venture capital financing for its R&D efforts to establish a method for predicting...
Ventyx Biosciences’ $176.6 Million Private Placement of Common Stock
Wilson Sonsini Goodrich & Rosati advised Ventyx Biosciences on the deal while Goodwin Procter represented Redmile Group. Ventyx Biosciences, Inc., a clinical-stage biopharmaceutical company focused on...
Boehringer Ingelheim’s Acquisition of Trutino Biosciences
Wilson Sonsini Goodrich & Rosati advised Trutino Biosciences on the deal. Boehringer Ingelheim, a leading research-driven biopharmaceutical company, announced the signing of an option to acquire...
Nalu Medical’s $104 Million Equity Financing
Wilson Sonsini advised Nalu Medical on the deal. Nalu Medical, Inc., a private company focused on innovative and minimally invasive solutions for chronic neuropathic pain, announced...
Ventyx’s $174 Million IPO
Wilson Sonsini Goodrich & Rosati advised Ventyx on the deal. Ventyx Biosciences, a clinical-stage biopharmaceutical company focused on advancing new therapies for millions of patients living...
Codex DNA’s $122 Million IPO
Wilson Sonsini Goodrich & Rosati advised Codex DNA on the deal. Codex DNA, Inc. (Nasdaq: DNAY) announced the closing of its initial public offering of 7,666,664...
Ventyx Biosciences’ $114 Million Equity Financing
Wilson Sonsini Goodrich & Rosati advised Ventyx Biosciences on the deal. Taylor Wessing advised Oppilan Pharma Limited and Zomagen Biosciences Limited. Ventyx Biosciences, a clinical-stage biotechnology...